---
document_datetime: 2025-08-26 15:08:19
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/dimethyl-fumarate-accord-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: dimethyl-fumarate-accord-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 4.966823
conversion_datetime: 2025-12-25 01:04:10.320883
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Dimethyl fumarate Accord

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency' s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessmenthistory'section.Forthe completeproduct lifecycleprocedures,you mayneedtoalsorefertoEPAR-Proceduralsteps taken andscientific informationafterauthorisation(archive).

| Applicationnumber    | Scope                                  | Opinion/ Notification 1 issued on   | Commission Decision IssuedÂ²/ amendedon   | Product Information affected3   | Summary   |
|----------------------|----------------------------------------|-------------------------------------|------------------------------------------|---------------------------------|-----------|
| Variation typeIA_IN/ | This was an application for a group of | 25/08/2025                          |                                          | Annex II and                    |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000292854                     | variations. B.II.b.1 Replacement or addition of a manufacturingsiteforpartor allofthe manufacturing process of the finished product - B.1I1.b.1.a Secondary packaging site -Accepted B.II.b.2.cReplacementor addition of a manufacturer responsibleforimportation and/or batch release - B.11.b.2.c.2 Including batch control/testing - Accepted                                                       |            |     | PL          |                                                                                                                                                                                  |
|---------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000253311 | C.1.11 Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation,including the risk managementplan-C.I.11.z Other RMP changes (e.g. agreed wording + template change)-Accepted Tobring theRMPinlinewiththeRMPof the reference product by e.g. removing the important identified risks; decreases in leukocyte and lymphocyte counts and drug induced liver injury. | 13/03/2025 | N/A |             | To bring the RMP in line with the reference product by e.g. removing the important identified risks; decreases in leukocyte and lymphocyte counts and drug induced liver injury. |
| Variation type IB / EMA/VR/0000247229 | Thiswas an applicationfor a group of variations. C.I.2 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet of a generic/hybrid/biosimilar medicinal                                                                                                                                                                                                                      | 10/03/2025 |     | SmPC and PL |                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

| products following assessment of the same change for the reference product-C.I.2.a Implementation of change(s) for which no new additional data is required to be submittedby theMAH-Accepted  C.I.2 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet of ageneric/hybrid/biosimilarmedicinal products following assessment of the same change for the reference product-C.I.2.a Implementation of change(s) for which no new additional dataisrequired tobe submittedby theMAH-Accepted  C.1.2.a (IB)-To update section 4.8 of the SmPCandsection4of thePackageLeaflet to change the frequency category of DILI (Drug-induced liver injury) from \"not known\" to\"rare\", following approval of the same changes in the reference product.C.I.2.a (IB) - To update sections 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 5.1, 5.2, and 5.3 of the SmPC, as well as sections 2 and 4 of the Package Leaflet,inordertoalignwiththereference product by bringing the annexes in line with theQRDtemplateandtheSmPCguideline.   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|